JP Morgan Reinstates Overweight on MBX Biosciences, Announces $88 Price Target

Benzinga Newsdesk www.benzinga.com Neutral 54.0%

Neg 0% Neu 54% Pos 0%

JP Morgan analyst Jessica Fye reinstates MBX Biosciences (NASDAQ:MBX) with a Overweight and announces $88 price target.

Comments

No comments yet. Be the first!